RBC Capital analyst Alistair Campbell lowered the firm’s price target on Genmab (GMAB) to DKK 2,300 from DKK 2,400 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab price target lowered to $45 from $50 at Truist
- William Blair upgrades Genmab with focus now on pipeline
- Genmab upgraded to Outperform from Market Perform at William Blair
- Expectations for J&J Genmab opt-in lowered ahead of news, says Morgan Stanley
- JPMorgan expects ‘significant’ underperformance of Genmab shares